Phase
            III
            randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (
            RADPAC
            )

Sylvie Lorenzen; Jorge Riera Knorrenschild; Claudia Pauligk; Susanna Hegewisch‐Becker; Jörg Seraphin; Peter Thuss‐Patience; Hans‐Georg Kopp; Tobias Dechow; Arndt Vogel; Kim Barbara Luley; Daniel Pink; Michael Stahl; Frank Kullmann; Holger Hebart; Jens Siveke; Matthias Egger; Nils Homann; Stephan Probst; Thorsten Oliver Goetze; Salah‐Eddin Al‐Batran

doi:10.1002/ijc.33025

Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC )

International Journal of Cancer ◽

10.1002/ijc.33025 ◽

2020 ◽

Vol 147 (9) ◽

pp. 2493-2502 ◽

Cited By ~ 1

Author(s):

Sylvie Lorenzen ◽

Jorge Riera Knorrenschild ◽

Claudia Pauligk ◽

Susanna Hegewisch‐Becker ◽

Jörg Seraphin ◽

...

Keyword(s):

Esophagogastric Junction ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Esophagogastric Junction Carcinoma

Download Full-text

Phase III Clinical Trial Comparing Iopamidol 250 mgI/mL and Iopamidol 300mgI/mL in Cerebral Angiography: Multicenteric, Randomized and Double Blind Study

Journal of the Korean Radiological Society ◽

10.3348/jkrs.2007.57.6.501 ◽

2007 ◽

Vol 57 (6) ◽

pp. 501

Author(s):

Hyobin Seo ◽

Moon Hee Han ◽

Bae Ju Kwon ◽

So Hyang Im ◽

Cheolkyu Jung ◽

...

Keyword(s):

Clinical Trial ◽

Cerebral Angiography ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Phase Iii Clinical Trial

Download Full-text

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkq254 ◽

2010 ◽

Vol 65 (Supplement 4) ◽

pp. iv41-iv51 ◽

Cited By ~ 64

Author(s):

G. R. Corey ◽

M. H. Wilcox ◽

G. H. Talbot ◽

D. Thye ◽

D. Friedland ◽

...

Keyword(s):

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Ceftaroline Fosamil ◽

Skin Structure ◽

Complicated Skin

Download Full-text

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

European Journal of Cancer ◽

10.1016/s0959-8049(99)80705-9 ◽

1999 ◽

Vol 35 ◽

pp. S84 ◽

Cited By ~ 2

Author(s):

E. Bajetta ◽

L.Y. Dirix ◽

L.E. Fein ◽

S.E. Jones ◽

J. Cervek ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Survival Advantage ◽

Advanced Breast ◽

Blind Study ◽

Megestrol Acetate ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind

Download Full-text

Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Annals of Oncology ◽

10.1093/annonc/mdz248.008 ◽

2019 ◽

Vol 30 ◽

pp. v330-v331

Author(s):

N. Agarwal ◽

K. McQuarrie ◽

A. Bjartell ◽

S. Chowdhury ◽

A J P D S Gomes ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Patient Reported Outcomes ◽

Androgen Deprivation ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Patient Reported

Download Full-text

Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis

Clinical Therapeutics ◽

10.1016/s0149-2918(00)83041-6 ◽

2000 ◽

Vol 22 (12) ◽

pp. 1421-1432 ◽

Cited By ~ 20

Author(s):

John J Murray ◽

Eric Solomon ◽

Dennis McCluskey ◽

Jie Zhang ◽

Robert Palmer ◽

...

Keyword(s):

Extended Release ◽

Maxillary Sinusitis ◽

Immediate Release ◽

Adult Patients ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind

Download Full-text

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Annals of Oncology ◽

10.1093/annonc/mdz394.027 ◽

2019 ◽

Vol 30 ◽

pp. v872-v873 ◽

Cited By ~ 24

Author(s):

G.K. Abou-Alfa ◽

T. Macarulla Mercade ◽

M. Javle ◽

R.K. Kelley ◽

S. Lubner ◽

...

Keyword(s):

Isocitrate Dehydrogenase ◽

Idh1 Mutation ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Isocitrate Dehydrogenase 1 ◽

Double Blind

Download Full-text

CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)

Annals of Oncology ◽

10.1093/annonc/mdv337.08 ◽

2015 ◽

Vol 26 ◽

pp. vi28 ◽

Cited By ~ 2

Author(s):

J.D. Wolchok ◽

V. Chiarion-Sileni ◽

R. Gonzalez ◽

P. Rutkowski ◽

J. Grob ◽

...

Keyword(s):

Advanced Melanoma ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind

Download Full-text

Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis

Clinical Therapeutics ◽

10.1016/s0149-2918(00)83040-4 ◽

2000 ◽

Vol 22 (12) ◽

pp. 1410-1420 ◽

Cited By ~ 23

Author(s):

Jay L Adler ◽

William Jannetti ◽

David Schneider ◽

Jie Zhang ◽

Robert Palmer ◽

...

Keyword(s):

Chronic Bronchitis ◽

Acute Exacerbation ◽

Extended Release ◽

Immediate Release ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind

Download Full-text

PB1762 A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY PLUS MIDOSTAURIN (PKC412) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 MUTATION NEGATIVE AML

HemaSphere ◽

10.1097/01.hs9.0000565556.35758.82 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 809-810

Author(s):

H. Döhner ◽

F. Lo-Coc ◽

G. Ossenkoppele ◽

J. Sierra ◽

B.-R. Bengoudifa ◽

...

Keyword(s):

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Newly Diagnosed ◽

Consolidation Chemotherapy ◽

Double Blind ◽

Flt3 Mutation

Download Full-text

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Annals of Oncology ◽

10.1093/annonc/mdy282.166 ◽

2018 ◽

Vol 29 ◽

pp. viii267-viii268 ◽

Cited By ~ 1

Author(s):

M.J. Jimenez Exposito ◽

M. Akce ◽

J.L. Montero Alvarez ◽

E. Assenat ◽

L.A. Balart ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

High Risk ◽

Curative Resection ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Risk Of Recurrence

Download Full-text